Rizatriptan Benzoate Tablet
Product Images NDC 68462-466

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 68462-466). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton-10mg (Carton 10mg)

Packaging label for Rizatriptan Benzoate Tablets 10 mg by Glenmark Pharmaceuticals Inc., USA. The label states the product contains 18 unit-dose tablets, is Rx only, and includes storage instructions and manufacturing information. The text highlights the 10 mg strength and the Glenmark logo appears multiple times.*

FDA Label Image

Carton-5mg (Carton 5mg)

The packaging label for Rizatriptan Benzoate Tablets, 5 mg strength, manufactured by Glenmark Pharmaceuticals Inc., USA. The label indicates 18 unit-dose tablets in the package, with storage instructions and a note that each tablet contains 7.265 mg of rizatriptan benzoate USP equivalent to 5 mg rizatriptan. The label also emphasizes Rx Only and provides the NDC 68462-465-99.*

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical structure diagram of rizatriptan benzoate, showing the molecular components and bonds of the active ingredient.*

FDA Label Image

Figure1 (Figure1)

A line graph depicting estimated probability of response over hours post-dose for rizatriptan benzoate tablets at 5 mg and 10 mg strengths compared to placebo. The x-axis represents hours post-dose from 0 to 2, and the y-axis shows the estimated probability of response ranging from 0% to 100%. Both tablet strengths show a higher probability of response than placebo, increasing over time.*

FDA Label Image

Figure2 (Figure2)

A line graph depicting the estimated probability of remediation of rescue over 24 hours post-dose. The graph compares placebo, rizatriptan benzoate 5 mg tablets, and rizatriptan benzoate 10 mg tablets, showing higher probabilities over time for the placebo group relative to the two dosage strengths.*

FDA Label Image

Figure3 (Figure3)

A line graph showing estimated probability of response over two hours post-dose comparing placebo, rizatriptan benzoate ODT 5 mg, and rizatriptan benzoate ODT 10 mg. The 10 mg dose shows the highest response probability, followed by 5 mg and placebo, with response increasing over time.*

FDA Label Image

Figure4 (Figure4)

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose for placebo, Rizatriptan benzoate ODT 5 mg, and Rizatriptan benzoate ODT 10 mg. The graph compares the three treatments with time on the x-axis and probability percentage on the y-axis.*

FDA Label Image

Figure5 (Figure5)

A line graph comparing the percentage response over time between Rizatriptan Benzoate and placebo groups. The x-axis represents hours post Stage 2 dose (0.5 to 2.0 hours), and the y-axis shows percent response with 95% confidence intervals. Two lines indicate higher response percentages for Rizatriptan Benzoate than placebo across the time points measured.*

FDA Label Image

Glenmark-logo (Glenmark Logo)

FDA Label Image

Glenmark-logo1 (Glenmark Logo1)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.